Media stories about Argos Therapeutics (NASDAQ:ARGS) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.9439558374934 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine raised shares of Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $24.00.
Shares of Argos Therapeutics (NASDAQ:ARGS) traded down $0.09 during trading on Wednesday, hitting $1.48. 227,400 shares of the company traded hands, compared to its average volume of 884,475. The company has a market cap of $9.64, a price-to-earnings ratio of -0.06 and a beta of 0.99. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46. Argos Therapeutics has a 12 month low of $1.40 and a 12 month high of $98.00.
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-argos-therapeutics-args-share-price.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.